Induction of Mitochondrial Dysfunction and Oxidative Damage by Antibiotic Drug Doxycycline Enhances the Responsiveness of Glioblastoma to Chemotherapy.
Unfortunately this used a subcutaneous, flank-injected tumor model, so it bypassed the critical issue of the blood-brain barrier. We do have several examples of intracranial glioma mouse models showing therapeutic effects for minocycline, which is in the same drug class as doxycycline. Based on these studies, minocycline is included in CUSP9v3, which is in clinical trial in Germany. See here for dosing: https://clinicaltrials.gov/ct2/show/NCT02770378
Unfortunately the phase 1 trial was not overly successful for an unselected GBM population. "A signal of efficacy was not seen. Further investigation of minocycline in unselected high grade glioma is not warranted, though biomarkers of NF-kappaB activation and mesenchymal phenotype are being investigated."
Unfortunately this used a subcutaneous, flank-injected tumor model, so it bypassed the critical issue of the blood-brain barrier. We do have several examples of intracranial glioma mouse models showing therapeutic effects for minocycline, which is in the same drug class as doxycycline. Based on these studies, minocycline is included in CUSP9v3, which is in clinical trial in Germany. See here for dosing:
ReplyDeletehttps://clinicaltrials.gov/ct2/show/NCT02770378
See also
Deletehttps://clinicaltrials.gov/ct2/show/NCT01580969
and
https://clinicaltrials.gov/ct2/show/NCT02272270
https://academic.oup.com/neuro-oncology/article-abstract/19/suppl_6/vi19/4590364?redirectedFrom=fulltext
Unfortunately the phase 1 trial was not overly successful for an unselected GBM population. "A signal of efficacy was not seen. Further investigation of minocycline in unselected high grade glioma is not warranted, though biomarkers of NF-kappaB activation and mesenchymal phenotype are being investigated."